Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Genitourinary tumours, non-prostate

4447 - Prognostic factors in metastatic seminomatous germ cell tumors and elevated human chorionic gonadotrophin (HCG) – a study of the G3

Date

29 Sep 2019

Session

Poster Discussion – Genitourinary tumours, non-prostate

Presenters

Christoph Seidel

Citation

Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249

Authors

C. Seidel1, G. Daugaard2, T. Nestler3, A. Tryakin4, C.D. Fankhauser5, T. Hermanns5, J. Aparicio6, J. Heinzelbecker7, P. Pfaffenholz3, U. De Giorgi8, R. Cathomas9, A. Lorch10, A. Fingerhut11, F. Gayer12, F. Bremmer12, P. Giannatempo13, A. Necchi13, G. Aurilio14, C. Oing1, C. Bokemeyer1

Author affiliations

  • 1 Department Of Oncology, Hematology And Bone Marrow Transplant With Pneumology, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, 20246 - Hamburg/DE
  • 2 Oncology, Rigshospitalet, Copenhagen University Hospital, 2100 - Copenhagen/DK
  • 3 Urology, University Hopsital Cologne, 50937 - Cologne/DE
  • 4 Oncology, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 5 Urology, Universitätsspital Zürich, 8091 - Zurich/CH
  • 6 Medical Oncology Department, Hospital La Fe, Valencia/ES
  • 7 Urology, University Clinic Saarland, 66424 - Homburg/Saar/DE
  • 8 Meloda, University Clinic Meloda, 47023 - Meloda/IT
  • 9 Oncology/hematology, Kantonsspital Graubünden, 7000 - Chur/CH
  • 10 Klinik Für Medizinische Onkologie Und Hämatologie, University Hospital Zürich, 8091 - Zurich/CH
  • 11 Urology, University Clinic Düsseldorf, +41 44 255 11 11 - Düsseldorf/DE
  • 12 Pathology, University Clinic Göttingen, 37099 - Göttingen/DE
  • 13 Medical Oncology, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 14 Oncology, Istituto Europeo di Oncologia, 20141 - Milan/IT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4447

Background

Seminomas do not express specific tumour markers, but in ∼30% of the patients (pts) serum HCG levels are elevated. This study investigates the prognostic impact of HCG levels and other characteristics in metastatic HCG-positive seminoma patients.

Methods

Patients with seminomatous histology, metastatic disease, serum HCG levels above normal without AFP elevations at diagnosis were eligible. Uni- and multivariable analyses were conducted to identify risk factors associated with survival outcomes. Cut-off values were determined by ROC curve analysis. Primary and secondary endpoints were overall survival (OS) and recurrence free survival (RFS), respectively.

Results

Our study identified 407 eligible patients diagnosed between 1984 and 2018 (334 pts good and 48 pts intermediate prognosis according to IGCCCG). The 5-year OS and 3-year RFS rates were 91% and 83%, respectively. HCG levels ranged from 1 IU/l to 283.782 IU/l (median: 33; IQR 142.5) pre- and 0 IU/l to 36.700 IU/l (median: 37; IQR 156.2) post-orchiectomy. Serum HCG levels pre-orchiectomy correlated with the UICC stage: mean HCG 826.9 IU/l in stage IIA-C vs. mean 4764.4 IU/l in stage IIIA-C (p < 0.001) and metastatic burden assessed by the largest axial diameter of metastasis: mean HCG 57.4 IU/l if < 7cm vs. mean 4.685 IU/l if ≥ 7cm (p = 0.012), respectively. Univariable analysis revealed LDH ≥1.5 UNL pre-orchiectomy (5-year OS: 87% vs. 97%, n = 91) (p = 0.019), age ≥40 years (5-year OS: 87% vs. 94%, n = 152) (p = 0.007), and HCG ≥2.000 IU/l pre-orchiectomy (5-year OS: 76% vs. 94%, n = 17) (p = 0.019) as poor prognostic factors concerning OS. Multivariable analysis confirmed LDH ≥1.5 UNL pre-orchiectomy (HR 3.88, 95%CI 1.97-16.25; p = 0.01), age ≥40 years (HR 5.97, 95%CI 1.82-17.15; p = 0.02), and HCG levels ≥2.000 IU/l pre-orchiectomy (HR 3.59, 95%CI 1.01-12.77; p = 0.048) as independent negative prognosticators for OS. No significant correlations were found between patient characteristics and the recurrence free survival.

Conclusions

HCG values correlate with the tumour stage and levels ≥2.000 IU/l are associated with an impaired outcome concerning OS. Our results should be considered for the risk stratification of HCG positive seminoma patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

T. Hermanns: Advisory / Consultancy: Bayer und MSD. U. De Giorgi: Research grant / Funding (self): AstraZeneca, Roche, Sanofi; Travel / Accommodation / Expenses: BMS, Ipsen, Janssen, Pfizer; Advisory / Consultancy: Astellas, Bayer, BMS, Ipsen, Janssen, Merck, Pfizer, Sanofi. R. Cathomas: Advisory / Consultancy: AstraZeneca, Astellas, Bayer, Janssen, Sanofi, BMS, MSD, Roche, Pfizer; Speaker Bureau / Expert testimony: Debiopharm, Astellas. C. Oing: Honoraria (self), Travel / Accommodation / Expenses: IPSEN, Medac; Research grant / Funding (institution): Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.